Skip to Content
Søg Menu
8.-16. juni 2023

Følg med når vi dækker EHA 2023 l European Hematology Association’s Annual Congress

Nyheder fra EHA 2022

Tillæg af andengenerations-FLT3-inhibitor til intensiv kemoterapi og konsolidering hos voksne med AML

  • / Daniel Kristensen

Højdepunkter fra EHA webinar 2022

Martin Hutchings

Hidtil højeste overall survival udfordrer 1.-linjebehandling ved Hodgkin lymfom

/ Martin Hutchings
Lymfom Play the Video
Martin Hutchings

To bispecifikke antistoffer er på vej mod godkendelse mod diffust storcellet B-celle lymfom

/ Martin Hutchings
Lymfom Play the Video
Carsten Utoft Niemann

Tidsbegrænset venetoclax-baseret kombinationsbehandling opnår bedre PFS og MRD-negativitet ved behandling af CLL

/ Carsten Utoft Niemann
CLL Play the Video
Carsten Utoft Niemann

Sekventering og vurdering af behandlingsforløb ved CLL

/ Carsten Utoft Niemann
EHA22CLL Play the Video

MEDtalks fra EHA 2022

AML

Nyt landsdækkende studie stiller spørgsmålstegn ved betydningen af dosisreduktion hos overvægtige AML-patienter

/ Hæmatologi / Daniel Kristensen

What Is the Best Treatment for Elderly Patients With AML?

/ Hæmatologi / Bjørn Tore Gjertsen

AML: Significant antiproliferative effect in vitro by pharmacological Rac1 inhibition

/ Hæmatologi / Anette Lodvir Hemsing

Significant improvements in OS and RFS for older patients with AML

/ Hæmatologi / Farhad Ravandi

EHA 2019: Intervention for AML patients with MRD can result in improved survival

/ Hæmatologi / Christopher Hourigan
Se oversigt

CLL

Sekventering og vurdering af behandlingsforløb ved CLL

/ Hæmatologi / Carsten Utoft Niemann

Tidsbegrænset venetoclax-baseret kombinationsbehandling opnår bedre PFS og MRD-negativitet ved behandling af CLL

/ Hæmatologi / Carsten Utoft Niemann

CLL14 study five-year results: Significantly superior efficacy for Ven-Obi

/ Hæmatologi / Othman Al-sawaf

The main clinical message from the Five-Year Analysis of Murano Study

/ Hæmatologi / Arnon P. Kater

Gut microbiome dysbiosis could be implicated in the pathogenesis of CLL

/ Hæmatologi / Tereza Faitova
Se oversigt

Lymfom

To bispecifikke antistoffer er på vej mod godkendelse mod diffust storcellet B-celle lymfom

/ Hæmatologi / Martin Hutchings

Hidtil højeste overall survival udfordrer 1.-linjebehandling ved Hodgkin lymfom

/ Hæmatologi / Martin Hutchings

Phase 1 Results in SIRPα Antibody CC-95251 in Combination with Rituximab in Patients with R/R NHL

/ Hæmatologi / Paolo Strati

Novel oral agent with promising result as second-line treatment option for patients with T-Cell Lymphoma

/ Hæmatologi / Jean-Marie Michot

Manageable safety profile and promising efficacy in heavily pretreated patients with R/R Non-Hodgin Lymphoma

/ Hæmatologi / Jean-Marie Michot
Se oversigt

Myelomatose

Værdien af højdosisbehandling som tillæg til Rvd induktion og konsolidering ved myelomatose

/ Hæmatologi / Agoston Gyula Szabo

A new randomized study suggests an improved depth of response and PFS for patients relapsing on Lenalidomide

/ Hæmatologi / Paul G. Richardson

Longer PFS and higher ORR for frailty patients with R/R Multiple Myeloma treated with PVd than Vd

/ Hæmatologi / Paul G. Richardson

A new study shows that PTCD and MRD are complementary and necessary for doing a whole assessment on patient-response for myeloma patients

/ Hæmatologi / Jakob Nordberg Nørgaard

Treatment with RVD + stem cell transplant achieved higher PFS vs RV alone In patients with newly diagnosed multiple myeloma

/ Hæmatologi / Paul G. Richardson
Se oversigt

Abstracts fra EHA 2022

Ibrutinib keeps on delivering now as first-line treatment for older patients with mantle cell lymphoma

/ Hæmatologi / BestPractice Nordic

Superior safety profile for decitabine vs chemotherapy for older patient with AML

/ Hæmatologi / BestPractice Nordic

A novel CAR-T cell therapy thas proven highly effective for patients with RRMM

/ Hæmatologi / BestPractice Nordic

A new phase 3 trial shows significantly prolonged overall survival for patients with AML

/ Hæmatologi / BestPractice Nordic

Improved PFS is achievable using targeted therapy combinations with venetoclax in fit patients with treatment naïve CLL 

/ Hæmatologi / BestPractice Nordic

Treatment of Burkitt lymphoma with DA-EPOCH-R is associated with significant less infectious complications, transfusions, and hospitalization days 

  • / BestPractice Nordic

Se highlights EHA webinar 2022

Carsten Utoft Niemann

Sekventering og vurdering af behandlingsforløb ved CLL

/ Carsten Utoft Niemann
EHA22CLL Play the Video
Martin Hutchings

To bispecifikke antistoffer er på vej mod godkendelse mod diffust storcellet B-celle lymfom

/ Martin Hutchings
Lymfom Play the Video
Carsten Utoft Niemann

Tidsbegrænset venetoclax-baseret kombinationsbehandling opnår bedre PFS og MRD-negativitet ved behandling af CLL

/ Carsten Utoft Niemann
CLL Play the Video
Martin Hutchings

Hidtil højeste overall survival udfordrer 1.-linjebehandling ved Hodgkin lymfom

/ Martin Hutchings
Lymfom Play the Video

Gå ikke glip af det nyeste fra Hæmatologi

Skriv dig på og få nye artikler, MEDtalks og magasiner i din indbakke

Send mig seneste nyt fra hæmatologi

Mere fra EHA 2022

Kirsten Grønbæk

Hvad har GDPR betydet for den nordiske forskningsscene? Vigtigste take-aways fra EHA med Kirsten Grønbæk

/ Kirsten Grønbæk
EHA22 Play the Video

The New Treatment Landscape of Multiple Myeloma in the Perspective of New Front-line Therapies

/ Claudio Cerchione
EHA22Myelomatose Play the Video
Carsten Utoft Niemann

Her er hvad Carsten Niemann konkluderer ud fra de seneste CCL studier

/ Carsten Utoft Niemann
EHA22CLL Play the Video

Mere fra EHA 2021

Iberdomide show promising efficacy in heavily pretreated patients with Relapsed/Refractory Multiple Myeloma

/ Sagar Lonial
EHA21Myelomatose Play the Video

Highlights fra EHA 2021 (2:2)

/ Fredrik Schjesvold / Agoston Gyula Szabo
EHA21Myelomatose Play the Audio

Highlights fra EHA 2021 (1:2)

/ Fredrik Schjesvold / Agoston Gyula Szabo
EHA21Myelomatose Play the Audio

EHA-ESMO Clinical Practice Guidelines for Multiple Myeloma

/ Fredrik Schjesvold
EHA21Myelomatose Play the Video

Potential to become the best treatment for multiple myeloma in history

/ Thierry Facon
EHA21Myelomatose Play the Video

New bispecific antibody with promising efficacy and safety profil for patients with relapsed/refractory Multiple Myeloma

/ Amrita Y. Krishnan
EHA21Myelomatose Play the Video
Læs mere

Azacitidin tolereredes generelt godt af ældre patienter med AML

/ BestPractice Nordic
AlderdomEHA21AML

First-in-human study of teclistamab for relapsed/refractory Multiple Myeloma

/ Niels van de Donk
EHA21Myelomatose Play the Video

Early responses for BCMA-directed CAR-T cell therapy in progressive MM after 1-3 prior lines of therapy

/ Mounzer Agha
EHA21Myelomatose Play the Video
Back to top